🚀 VC round data is live in beta, check it out!
Biohaven Overview
About Biohaven
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Founded
2022
HQ
Employees
256
Website
Sectors
Financials (LTM)
EV
$1B
Biohaven Financials
Biohaven reported last 12-month revenue of — and negative EBITDA of ($619M).
In the same LTM period, Biohaven generated ($604K) in gross profit, ($619M) in EBITDA losses, and had net loss of ($653M).
Revenue (LTM)
Biohaven P&L
In the most recent fiscal year, Biohaven reported revenue of — and EBITDA of ($707M).
Biohaven expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | ($604K) | XXX | — | XXX | XXX | XXX |
| EBITDA | ($619M) | XXX | ($707M) | XXX | XXX | XXX |
| Net Profit | ($653M) | XXX | ($739M) | XXX | XXX | XXX |
| Net Debt | — | — | $9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biohaven Stock Performance
Biohaven has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Biohaven's stock price is $9.39.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.1% | XXX | XXX | XXX | $-4.91 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiohaven Valuation Multiples
Biohaven trades at (2.2x) EV/EBITDA.
EV / Revenue (LTM)
Biohaven Financial Valuation Multiples
As of April 11, 2026, Biohaven has market cap of $1B and EV of $1B.
Equity research analysts estimate Biohaven's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biohaven has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/EBITDA | (2.2x) | XXX | (1.9x) | XXX | XXX | XXX |
| EV/EBIT | (2.1x) | XXX | (1.8x) | XXX | XXX | XXX |
| EV/Gross Profit | (2279.6x) | XXX | — | XXX | XXX | XXX |
| P/E | (2.2x) | XXX | (1.9x) | XXX | XXX | XXX |
| EV/FCF | (3.1x) | XXX | (2.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biohaven Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biohaven Margins & Growth Rates
Biohaven's revenue in the last fiscal year grew by —.
Biohaven's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.9M for the same period.
Biohaven Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (38%) | XXX | (45%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biohaven Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Immatics | XXX | XXX | XXX | XXX | XXX | XXX |
| MoonLake | XXX | XXX | XXX | XXX | XXX | XXX |
| Novavax | XXX | XXX | XXX | XXX | XXX | XXX |
| Harrow | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangxi Fushine Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biohaven M&A Activity
Biohaven acquired XXX companies to date.
Last acquisition by Biohaven was on XXXXXXXX, XXXXX. Biohaven acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biohaven
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiohaven Investment Activity
Biohaven invested in XXX companies to date.
Biohaven made its latest investment on XXXXXXXX, XXXXX. Biohaven invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biohaven
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biohaven
| When was Biohaven founded? | Biohaven was founded in 2022. |
| Where is Biohaven headquartered? | Biohaven is headquartered in United States. |
| How many employees does Biohaven have? | As of today, Biohaven has over 256 employees. |
| Who is the CEO of Biohaven? | Biohaven's CEO is Vlad Coric. |
| Is Biohaven publicly listed? | Yes, Biohaven is a public company listed on NYSE. |
| What is the stock symbol of Biohaven? | Biohaven trades under BHVN ticker. |
| When did Biohaven go public? | Biohaven went public in 2022. |
| Who are competitors of Biohaven? | Biohaven main competitors are Immatics, MoonLake, Novavax, Harrow. |
| What is the current market cap of Biohaven? | Biohaven's current market cap is $1B. |
| Is Biohaven profitable? | No, Biohaven is not profitable. |
| What is the current EBITDA of Biohaven? | Biohaven has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Biohaven? | Current EBITDA multiple of Biohaven is (2.2x). |
| What is the current FCF of Biohaven? | Biohaven's last 12 months FCF is ($443M). |
| What is the current EV/FCF multiple of Biohaven? | Current FCF multiple of Biohaven is (3.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.